Literature DB >> 12571456

Brain uptake of the acid metabolites of F-18-labeled WAY 100635 analogs.

Richard E Carson1, Yanjun Wu, Lixin Lang, Ying Ma, Margaret G Der, Peter Herscovitch, William C Eckelman.   

Abstract

The 5-HT1A ligands [ 18F]FPWAY and [ 18F]FCWAY are metabolized to [ 18F]fluorobenzoic acid (FB) and [ 18F]fluorocyclohexanecarboxylic acid (FC), respectively. To quantify the penetration of these acids into the brain, dynamic positron emission tomography studies were performed in rhesus monkeys with [ 18F]FB and [ 18F]FC. High-performance liquid chromatography analysis of arterial blood samples showed no metabolites for [ 18F]FB, whereas [ 18F]FC was rapidly metabolized to [ 18F]fluoride. A model with one tissue compartment and vascular radioactivity was used to analyze gray matter time-activity curves. For [ 18F]FC, an additional term was added to account for [ 18F]fluoride skull spillover into the brain; this term accounted for 70% to 90% of the measured radioactivity concentration at 90 minutes. For [ 18F]FB, mean gray matter parameters were as follows: K1, 10 +/- 3 micro L. min(-1). mL(-1); distribution volume, 0.052 +/- 0.006 (mL/mL). For [ 18F]FC, the values were as follows: K1, 15 +/- 4 micro L. min(-1). mL(-1); V, 0.29 +/- 0.06 mL/mL. The values were consistent with a physiologic model that included brain-to-blood pH difference and the plasma free fraction of the acid. Simulations based on [ 18F]FCWAY human data showed that [ 18F]FC uptake produces significant biases in estimates in regions with low specific binding. These results can be used to correct the tissue [ 18F]FCWAY time-activity data for brain uptake of [ 18F]FC using the measured [ 18F]FC input function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12571456     DOI: 10.1097/01.WCB.0000046145.31247.7A

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  22 in total

1.  Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [123I]epidepride SPET.

Authors:  Masahiro Fujita; Andrea Varrone; Kyeong Min Kim; Hiroshi Watabe; Sami S Zoghbi; Nicholas Seneca; Dnyanesh Tipre; John P Seibyl; Robert B Innis; Hidehiro Iida
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-17       Impact factor: 9.236

2.  Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates.

Authors:  Nicolas Tournier; Salvatore Cisternino; Marie-Anne Peyronneau; Sébastien Goutal; Frédéric Dolle; Jean-Michel Scherrmann; Michel Bottlaender; Wadad Saba; Héric Valette
Journal:  Pharm Res       Date:  2012-05-30       Impact factor: 4.200

3.  An automated one-step one-pot [(18)F]FCWAY synthesis: development and minimization of chemical impurities.

Authors:  Bik-Kee Vuong; Dale O Kiesewetter; Lixin Lang; Ying Ma; William C Eckelman; Michael A Channing
Journal:  Nucl Med Biol       Date:  2007-05       Impact factor: 2.408

4.  18F-FCWAY and 18F-FDG PET in MRI-negative temporal lobe epilepsy.

Authors:  Clarissa J Liew; Young-Min Lim; Robert Bonwetsch; Sadat Shamim; Susumu Sato; Patricia Reeves-Tyer; Peter Herscovitch; Irene Dustin; Anto Bagic; Giampiero Giovacchini; William H Theodore
Journal:  Epilepsia       Date:  2008-09-17       Impact factor: 5.864

5.  First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors.

Authors:  Ansel T Hillmer; Dustin W Wooten; Alisha K Bajwa; Andrew T Higgins; Patrick J Lao; Tobey J Betthauser; Todd E Barnhart; Howard A Rowley; Charles K Stone; Sterling C Johnson; Jogeshwar Mukherjee; Bradley T Christian
Journal:  J Nucl Med       Date:  2014-11-13       Impact factor: 10.057

6.  Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.

Authors:  Nicholas Seneca; Balázs Gulyás; Andrea Varrone; Magnus Schou; Anu Airaksinen; Johannes Tauscher; Francois Vandenhende; William Kielbasa; Lars Farde; Robert B Innis; Christer Halldin
Journal:  Psychopharmacology (Berl)       Date:  2006-08-04       Impact factor: 4.530

7.  In vivo kinetics of [F-18]MEFWAY: a comparison with [C-11]WAY100635 and [F-18]MPPF in the nonhuman primate.

Authors:  D W Wooten; J D Moraino; A T Hillmer; J W Engle; O J Dejesus; D Murali; T E Barnhart; R J Nickles; R J Davidson; M L Schneider; J Mukherjee; B T Christian
Journal:  Synapse       Date:  2010-12-08       Impact factor: 2.562

8.  5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction.

Authors:  Giampiero Giovacchini; Maria T Toczek; Robert Bonwetsch; Anto Bagic; Lixin Lang; Charles Fraser; Pat Reeves-Tyer; Peter Herscovitch; William C Eckelman; Richard E Carson; William H Theodore
Journal:  J Nucl Med       Date:  2005-07       Impact factor: 10.057

9.  Synthesis and initial evaluation of [11C](R)-RWAY in monkey-a new, simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET.

Authors:  Julie A McCarron; Sami S Zoghbi; H Umesha Shetty; Eric S Vermeulen; Håkan V Wikström; Masanori Ichise; Fumihiko Yasuno; Christer Halldin; Robert B Innis; Victor W Pike
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-20       Impact factor: 9.236

10.  Using cerebral white matter for estimation of nondisplaceable binding of 5-HT1A receptors in temporal lobe epilepsy.

Authors:  Giampiero Giovacchini; Shielah Conant; Peter Herscovitch; William H Theodore
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.